Case Study #5: CXCR4-Targeted Radiotherapeutics

Andreas K. Buck; Heribert Hänscheid; Sebastian E. Serfling; Takahiro Higuchi; Leo Rasche; Hermann Einsele; Rudolf A. Werner

doi:10.1007/978-3-031-39005-0_15

Case Study #5: CXCR4-Targeted Radiotherapeutics

Andreas K. Buck
, Heribert Hänscheid
, Sebastian E. Serfling
, Takahiro Higuchi
, Leo Rasche
, Hermann Einsele
, Rudolf A. Werner

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Radiopharmaceutical therapy (RPT) has become a mainstay of modern oncology but remains limited to solid tumors, including orphan diseases such as neuroendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is composed of [⁶⁸Ga]Ga-PentixaFor (for positron emission tomography, PET) and [¹⁷⁷Lu]Lu-/[⁹⁰Y]Y-PentixaTher (for RPT via β-emission). Beyond its anti-lymphoma and anti-tumor effects, this treatment strategy also causes (desired) bone marrow ablation and thus helps condition patients for hematopoietic stem cell transplantation (HSCT) in tandem with planned high-dose chemotherapeutic regimens. In this chapter, we will summarize how PentixaFor/PentixaTher can (a) improve the delineation of the current status of tumor/lymphoma spread, (b) help identify candidates for CXCR4-targeted radioligand therapy, (c) achieve durable anti-lymphoma efficacy, and (d) prepare patients for HSCT. Such a complex, theranostic strategy requires a multidisciplinary team, including experts in hemato-oncology, gastroenterology, endocrinology, nuclear medicine, radiology, medical physics, and radiochemistry.

Original language	English
Title of host publication	Radiopharmaceutical Therapy
Publisher	Springer International Publishing
Pages	319-333
Number of pages	15
ISBN (Electronic)	9783031390050
ISBN (Print)	9783031390043
DOIs	https://doi.org/10.1007/978-3-031-39005-0_15
Publication status	Published - Jan 1 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

C-X-C motif chemokine receptor 4
CXCR4
Hematological malignancies
Lymphoma
PentixaFor
PentixaTher
Theranostics

ASJC Scopus subject areas

General Medicine
General Chemistry
General Biochemistry,Genetics and Molecular Biology

Access to Document

10.1007/978-3-031-39005-0_15

Cite this

@inbook{114214fe120747eeb961b6b3b08d7f71,

title = "Case Study \#5: CXCR4-Targeted Radiotherapeutics",

abstract = "Radiopharmaceutical therapy (RPT) has become a mainstay of modern oncology but remains limited to solid tumors, including orphan diseases such as neuroendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is composed of [68Ga]Ga-PentixaFor (for positron emission tomography, PET) and [177Lu]Lu-/[90Y]Y-PentixaTher (for RPT via β-emission). Beyond its anti-lymphoma and anti-tumor effects, this treatment strategy also causes (desired) bone marrow ablation and thus helps condition patients for hematopoietic stem cell transplantation (HSCT) in tandem with planned high-dose chemotherapeutic regimens. In this chapter, we will summarize how PentixaFor/PentixaTher can (a) improve the delineation of the current status of tumor/lymphoma spread, (b) help identify candidates for CXCR4-targeted radioligand therapy, (c) achieve durable anti-lymphoma efficacy, and (d) prepare patients for HSCT. Such a complex, theranostic strategy requires a multidisciplinary team, including experts in hemato-oncology, gastroenterology, endocrinology, nuclear medicine, radiology, medical physics, and radiochemistry.",

keywords = "C-X-C motif chemokine receptor 4, CXCR4, Hematological malignancies, Lymphoma, PentixaFor, PentixaTher, Theranostics",

author = "Buck, \{Andreas K.\} and Heribert H{\"a}nscheid and Serfling, \{Sebastian E.\} and Takahiro Higuchi and Leo Rasche and Hermann Einsele and Werner, \{Rudolf A.\}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-3-031-39005-0\_15",

language = "English",

isbn = "9783031390043",

pages = "319--333",

booktitle = "Radiopharmaceutical Therapy",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Case Study #5

T2 - CXCR4-Targeted Radiotherapeutics

AU - Buck, Andreas K.

AU - Hänscheid, Heribert

AU - Serfling, Sebastian E.

AU - Higuchi, Takahiro

AU - Rasche, Leo

AU - Einsele, Hermann

AU - Werner, Rudolf A.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Radiopharmaceutical therapy (RPT) has become a mainstay of modern oncology but remains limited to solid tumors, including orphan diseases such as neuroendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is composed of [68Ga]Ga-PentixaFor (for positron emission tomography, PET) and [177Lu]Lu-/[90Y]Y-PentixaTher (for RPT via β-emission). Beyond its anti-lymphoma and anti-tumor effects, this treatment strategy also causes (desired) bone marrow ablation and thus helps condition patients for hematopoietic stem cell transplantation (HSCT) in tandem with planned high-dose chemotherapeutic regimens. In this chapter, we will summarize how PentixaFor/PentixaTher can (a) improve the delineation of the current status of tumor/lymphoma spread, (b) help identify candidates for CXCR4-targeted radioligand therapy, (c) achieve durable anti-lymphoma efficacy, and (d) prepare patients for HSCT. Such a complex, theranostic strategy requires a multidisciplinary team, including experts in hemato-oncology, gastroenterology, endocrinology, nuclear medicine, radiology, medical physics, and radiochemistry.

AB - Radiopharmaceutical therapy (RPT) has become a mainstay of modern oncology but remains limited to solid tumors, including orphan diseases such as neuroendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is composed of [68Ga]Ga-PentixaFor (for positron emission tomography, PET) and [177Lu]Lu-/[90Y]Y-PentixaTher (for RPT via β-emission). Beyond its anti-lymphoma and anti-tumor effects, this treatment strategy also causes (desired) bone marrow ablation and thus helps condition patients for hematopoietic stem cell transplantation (HSCT) in tandem with planned high-dose chemotherapeutic regimens. In this chapter, we will summarize how PentixaFor/PentixaTher can (a) improve the delineation of the current status of tumor/lymphoma spread, (b) help identify candidates for CXCR4-targeted radioligand therapy, (c) achieve durable anti-lymphoma efficacy, and (d) prepare patients for HSCT. Such a complex, theranostic strategy requires a multidisciplinary team, including experts in hemato-oncology, gastroenterology, endocrinology, nuclear medicine, radiology, medical physics, and radiochemistry.

KW - C-X-C motif chemokine receptor 4

KW - CXCR4

KW - Hematological malignancies

KW - Lymphoma

KW - PentixaFor

KW - PentixaTher

KW - Theranostics

UR - https://www.scopus.com/pages/publications/85196458204

UR - https://www.scopus.com/pages/publications/85196458204#tab=citedBy

U2 - 10.1007/978-3-031-39005-0_15

DO - 10.1007/978-3-031-39005-0_15

M3 - Chapter

AN - SCOPUS:85196458204

SN - 9783031390043

SP - 319

EP - 333

BT - Radiopharmaceutical Therapy

PB - Springer International Publishing

ER -

Case Study #5: CXCR4-Targeted Radiotherapeutics

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this